Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

NU6140

CDK/cyclin inhibitor
 
ALX-270-441-M005 5 mg 158.00 USD
Do you need bulk/larger quantities?
 
Highly cell permeable purine compound that acts as a selective and ATP-competitive inhibitor of CDKs (IC50=6.6µM, 0.41µM, 5.5µM, 15µM and 3.9µM for CDK1/cyclin B, CDK2/cyclin A, CDK4/cyclin D, CDK5/p25 and CDK7/cyclin H) and displays anticancer properties. Causes cell cycle arrest at the G2/M phase and induces apoptosis by activating caspases and downregulating survivin.

Product Specification

Alternative Name:4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide
 
Formula:C23H30N6O2
 
MW:422.5
 
CAS:444723-13-1
 
Purity:≥95% (HPLC)
 
Identity:Determined by 1H-NMR and MS.
 
Appearance:White to off-white solid.
 
Solubility:Soluble in DMSO (10mg/ml).
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Use/Stability:Stock solutions are stable for up to 6 months when stored at -20°C.
 
Handling:Protect from light. Packaged under inert gas.
 
270-441
Please mouse over
270-441

Product Literature References

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation: M. Pennati, et al.; Mol. Cancer Ther. 4, 1328 (2005), Abstract;

Related Literature

Product Flyers
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,